Thus, pretreatment CEA ≥10 ng ml-1 and age > 60 years should be taken into account in the individualized medicine in adjuvant chemotherapy of CRC to reduce the risk of chemotherapy-associated lymphopenia and improve survival. Here, CEACAM5 is linked to colorectal carcinoma.